Refining risk stratification of patients with early breast cancer eligible for adjuvant abemaciclib or ribociclib

Clicks: 1
ID: 325006
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #325 of 329 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 329 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Optimal indications for adjuvant CDK4/6 inhibitors in hormone receptor-positive/HER2-negative early breast cancer remain debated, partly because monarchE and NATALEE trials used different eligibility criteria. Using pooled individual patient-level data from three randomized trials conducted before adjuvant CDK4/6 inhibitors (N = 4,795), we estimated baseline prognosis in eligibility-defined subgroups. Among patients with 1-3 positive lymph nodes (N1; N = 1,646), monarchE high-risk features (tumor size ≥5 cm and/or grade 3) identified a subgroup of patients (N = 493) with worse disease-free survival (HR 1.56; 95% CI 1.27-1.92) and overall survival (HR 1.78; 95% CI 1.34-2.36). Among patients meeting NATALEE-only eligibility criteria (N = 1,346), nodal status (N1 vs N0) did not meaningfully discriminate 7-year outcomes. In simulating prognosis among women treated in the pre-CDK4/6 inhibitor era and meeting varying monarchE and NATALEE eligibility criteria, these data may inform future trial design and clinical practice and stimulate efforts to refine clinical, pathological and molecular criteria for patient selection.
Reference Key
openalex_W7203460153 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Luca Arecco, Eva Blondeaux, Marco Bruzzone, Evandro de Azambuja, Matteo Lambertini, Lucia Del Mastro
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag264
URL
https://doi.org/10.1093/jnci/djag264
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.